Christopher Gasink

Statistics

Publications

Citations

H-Index

Active since

2011

Affiliations

Janssen (United States)(Current)

University of California San Diego

Janssen Scientific Affairs (United States)

Icahn School of Medicine at Mount Sinai

Western University

Christopher Gasink is an author at Janssen (United States) specializing in inflammatory bowel disease therapy, ustekinumab therapy, and inflammatory bowel disease.

Publications per year

2011–2024

Publications

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

William J. Sandborn, Christopher Gasink, Long-Long Gao et al. · New England Journal of Medicine · 2012 · 1.1K citations

Life Sciences, Immunology, Pharmacotherapy +17

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink et al. · Gastroenterology · 2018 · 250 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

William J. Sandborn, Rory Rebuck, Yuhua Wang et al. · Clinical Gastroenterology and Hepatology · 2021 · 240 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

1–5 of 29